What it's for (Indications)
- Empagliflozin + linagliptin, commonly found under brand names such as Glyxambi, is a fixed-dose combination medication indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- This combination therapy is particularly beneficial for patients who have not achieved adequate glycemic targets with either empagliflozin or linagliptin alone, or for those already on both components separately.
- Furthermore, empagliflozin, a component of this combination, has demonstrated benefits in reducing the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, and in reducing the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (HFrEF and HFpEF), with or without type 2 diabetes.
- The linagliptin component contributes to its overall efficacy in blood glucose management by enhancing incretin hormone activity.
- This comprehensive approach addresses multiple pathophysiological defects of type 2 diabetes.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage for empagliflozin + linagliptin is one tablet once daily, taken in the morning, with or without food. The available fixed-dose combinations typically include empagliflozin 10 mg/linagliptin 5 mg and empagliflozin 25 mg/linagliptin 5 mg. The choice of initial dose should be individualized based on the patient's current treatment regimen, glycemic control, and tolerability. For patients already on linagliptin, the initial dose can be empagliflozin 10 mg/linagliptin 5 mg. For patients already on empagliflozin, the dose should be based on their current empagliflozin dosage (10 mg or 25 mg), combined with linagliptin 5 mg. It is crucial to assess renal function prior to initiation and periodically thereafter. Dosage adjustment may be required in patients with moderate renal impairment, and the medication is contraindicated in severe renal impairment (eGFR <30 mL/min/1.73 m²), end-stage renal disease, or dialysis. Careful adherence to prescribing information is essential to optimize therapeutic outcomes and minimize adverse effects. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects of empagliflozin + linagliptin include urinary tract infections (UTIs), nasopharyngitis, upper respiratory tract infection, cough, diarrhea, constipation, and headache.
- Due to the SGLT2 inhibitor component (empagliflozin), patients may experience increased urination (polyuria) and volume depletion, which can lead to hypotension and dizziness, particularly in elderly patients or those on diuretics.
- More serious, albeit less common, adverse reactions include diabetic ketoacidosis (DKA), Fournier's gangrene (necrotizing fasciitis of the perineum), acute kidney injury, hypoglycemia (especially when used in combination with insulin or sulfonylureas), and hypersensitivity reactions.
- The DPP-4 inhibitor component (linagliptin) has been associated with pancreatitis, severe arthralgia, and bullous pemphigoid.
- Patients should be counseled on recognizing symptoms of these serious side effects and seeking immediate medical attention if they occur, ensuring prompt intervention and improved patient safety outcomes.
- Regular monitoring and patient education are key to managing potential adverse events.
Serious Warnings
- Black Box Warning: **Serious Warnings** While empagliflozin + linagliptin does not carry an FDA Black Box Warning, several serious and potentially life-threatening adverse events warrant careful consideration and vigilant patient monitoring. These include **diabetic ketoacidosis (DKA)**, which can occur with SGLT2 inhibitors even in patients with only moderately elevated glucose levels. Prompt recognition of symptoms like nausea, vomiting, abdominal pain, fatigue, and dyspnea, followed by immediate discontinuation of the medication and appropriate medical intervention, is essential. **Fournier's gangrene**, a severe, rapidly progressing, and potentially fatal necrotizing fasciitis of the perineum, has been reported with SGLT2 inhibitors. Patients must be instructed to seek immediate medical attention for any pain, tenderness, erythema, or swelling in the genital or perineal area, especially if accompanied by fever or malaise. **Acute kidney injury** and **volume depletion** (leading to symptomatic hypotension) are risks, particularly in vulnerable populations such as the elderly, patients with pre-existing renal impairment, or those on loop diuretics; renal function and volume status should be monitored closely. **Pancreatitis** and **severe disabling arthralgia** are associated with the linagliptin component. Providers should be vigilant for symptoms of these serious conditions and counsel patients thoroughly on their potential occurrence and the importance of timely reporting.
- Patients receiving empagliflozin + linagliptin must be closely monitored for several serious conditions.
- Diabetic ketoacidosis (DKA), a life-threatening condition, has been reported in patients taking SGLT2 inhibitors, even with only moderately elevated blood glucose levels.
- Patients presenting with symptoms of DKA should have the medication discontinued immediately, and appropriate measures taken.
- Rare but serious cases of Fournier's gangrene (necrotizing fasciitis of the perineum) have been observed with SGLT2 inhibitors; patients should be advised to seek immediate medical attention for pain, tenderness, erythema, or swelling in the genital or perineal area, accompanied by fever or malaise.
- Volume depletion, leading to symptomatic hypotension, can occur, particularly in the elderly, patients with renal impairment, or those on loop diuretics.
- Acute kidney injury has been reported, necessitating renal function monitoring.
- Pancreatitis and severe disabling arthralgia have been associated with DPP-4 inhibitors like linagliptin.
- Hypersensitivity reactions, including angioedema and exfoliative skin conditions, may occur.
- Regular monitoring of renal function, blood glucose, and patient counseling on symptom recognition are crucial for safe use and to mitigate risks.
How it Works (Mechanism of Action)
Empagliflozin + linagliptin combines two distinct and complementary mechanisms of action to improve glycemic control in type 2 diabetes. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. It acts in the kidneys, specifically at the proximal renal tubules, to inhibit SGLT2. By doing so, it reduces the reabsorption of filtered glucose from the tubular lumen back into the blood, leading to increased urinary glucose excretion (glucosuria). This mechanism is independent of insulin secretion and sensitivity, resulting in a reduction in blood glucose levels. It also leads to mild osmotic diuresis and natriuresis. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by preventing the rapid enzymatic breakdown of incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Higher circulating levels of these active incretin hormones lead to increased glucose-dependent insulin synthesis and release from pancreatic beta cells, and decreased glucagon secretion from pancreatic alpha cells. This combination synergistically lowers both fasting and postprandial glucose levels while addressing different pathophysiological pathways of type 2 diabetes, providing comprehensive glycemic management with a reduced risk of hypoglycemia compared to some other antidiabetic agents.